Insider Transactions and Holdings
-
Entity Type
-
Individual
-
Role
-
Director
-
Issuer Symbol
-
LXRX on Nasdaq
Raymond Debbane - trading volume in the past year for LEXICON PHARMACEUTICALS, INC.
| Security |
Num Shares |
Value |
Price $ |
Transaction Date |
Ownership |
Underlying Class |
Underlying Amount |
| Common Stock |
35,402,689 |
$53,104,033 |
$1.50 |
25 Feb 2026 |
By Invus, L.P. and related parties |
|
|
| Common Stock |
7,362,368 |
$11,043,552 |
$1.50 |
25 Feb 2026 |
By Invus Public Equities, L.P. and related parties |
|
|
| Common Stock |
5,451,204 |
$8,176,806 |
$1.50 |
25 Feb 2026 |
By Invus US Partners, LLC and related parties |
|
|
| Common Stock |
1,906,186 |
$2,840,217 |
$1.49 |
25 Feb 2026 |
Direct |
|
|
| Common Stock |
1,538,462 |
$2,307,693 |
$1.50 |
25 Feb 2026 |
By Avicenna Life Sci Master Fund LP and related parties |
|
|
| Restricted Stock Units |
89,312 |
$96,442 |
$2.62 |
03 Jun 2025 |
Direct |
Common Stock |
|
| Stock Option (Right to Buy) |
103,806 |
|
|
03 Jun 2025 |
Direct |
Common Stock |
|
| Sym |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.